Author

Motoyasu Chibai 1

1 Heiwadai Clinic, Department of Gastroenterology, Tokyo, Japan

ESOMEPRAZOLE BASED TRIPLE THERAPY REGIMENS (EAC/EAM) ON H.PYLORI ERADICATION THERAPY SHOWED HIGH SUCCESS RATE EVEN IF ON EM OF CYP2C19 POLYMORPHISM OR CAM RESISTANCE.

Takuji Yamasaki, Motoyasu Chibai, Takashi Nakayoshi, Shiro Watanabe

HIGH DOSE CAM WITH VONOPRAZAN (P-CAB) PLUS AMX TRIPLE THERAPY REGIMEN IS THE STRONGEST H.PYLORI ERADICATION THERAPY EVEN IF CAM RESISTANCE.  

Takuji Yamasaki, Toshiyuki Sakurai, Jimi Mitobe, Masato Mitsunaga, Yuki Amano, Yoshitaka Tokai, Motoyasu Chibai, Masayuki Saruta

HIGH DOSE CLARITHROMYCIN WITH P-CAB PLUS AMOXICILLIN TRIPLE THERAPY REGIMEN IS MOST RECOMMENDED ON 1<sup>ST</sup> H.PYLORI ERADICATION REGIMEN; A MULTICENTER CENTER PROSPECTIVE CASE STUDY

Takuji Yamasaki, Motoyasu Chibai, Yoshinori Arai, Eri Nishio, Mashu Aizawa, Yasushi Nakamura, Masayuki Saruta

Measurement of serum gastrin levels and histologic evaluation of the degree of parietal cell degeneration and ECL cell hyperplasia are the most important indicators to evaluate the risk of developing NET when considering the use of more potent gastric acid secretion inhibitors

Takuji Yamasaki, Motoyasu Chibai, Toshiyuki Sakurai, Yoshihiro Akita, Yuki Maruyama, Ryosuke Miyazaki, Haruna Miyashita, Makoto MItsunaga, Tomohiro Kato, Masayuki Saruta

SURFACE IRREGULARITIES OCCURRING IN THE GASTRIC MUCOSA AFTER H. PYLORI ERADICATION MAKES IT DIFFICULT FOR ENDOSCOPIC DIAGNOSIS OF GASTRIC CANCER DETECTING

Takuji Yamasaki, Motoyasu Chibai, Toshiyuki Sakurai, Jimi Mitobe, Masayuki Saruta, Kazuki Sumiyama

Item 1 - 5 / 5
1